Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data.

IF 4 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Safety Pub Date : 2025-02-20 DOI:10.1007/s40264-025-01522-z

Nina L Wittwer, Christoph R Meier, Carola A Huber, Henriette E Meyer Zu Schwabedissen, Samuel Allemann, Cornelia Schneider

{"title":"Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data.","authors":"Nina L Wittwer, Christoph R Meier, Carola A Huber, Henriette E Meyer Zu Schwabedissen, Samuel Allemann, Cornelia Schneider","doi":"10.1007/s40264-025-01522-z","DOIUrl":null,"url":null,"abstract":"Background: In Switzerland, consumers are exposed to drugs with pharmacogenetic (PGx) recommendations in 78% of cases. Pre-emptive PGx testing for seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) has been covered by basic health insurance since 2017. PGx testing for other drugs is only covered if it is reactive and prescribed by a clinical pharmacologist. No data are yet available on the implementation of PGx testing in the outpatient setting.Aim: The objective of this study was to determine the prevalence of ambulatory PGx testing in the Swiss population, to characterize PGx-tested individuals, and to identify the most commonly used drugs before and after PGx testing.Methods: We assessed the prevalence of PGx testing in Switzerland and characterized individuals who underwent PGx testing between 2017 and 2021 using claims data from a large health insurance company.Results: Of 894,748 individuals registered for the entire study period, only 817 (0.09%) underwent PGx testing. Those who underwent PGx testing were more frequently female and claimed more drugs and PGx drugs than those who did not undergo PGx testing. The drugs used before and after PGx testing differed, and fewer drugs with reimbursement for pre-emptive PGx testing were included before PGx testing.Conclusion: In Switzerland, personalized pharmacotherapy has the potential to be improved, as only 0.09% of the studied population underwent PGx testing, despite 77.4% claiming PGx drugs.","PeriodicalId":11382,"journal":{"name":"Drug Safety","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40264-025-01522-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In Switzerland, consumers are exposed to drugs with pharmacogenetic (PGx) recommendations in 78% of cases. Pre-emptive PGx testing for seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) has been covered by basic health insurance since 2017. PGx testing for other drugs is only covered if it is reactive and prescribed by a clinical pharmacologist. No data are yet available on the implementation of PGx testing in the outpatient setting.

Aim: The objective of this study was to determine the prevalence of ambulatory PGx testing in the Swiss population, to characterize PGx-tested individuals, and to identify the most commonly used drugs before and after PGx testing.

Methods: We assessed the prevalence of PGx testing in Switzerland and characterized individuals who underwent PGx testing between 2017 and 2021 using claims data from a large health insurance company.

Results: Of 894,748 individuals registered for the entire study period, only 817 (0.09%) underwent PGx testing. Those who underwent PGx testing were more frequently female and claimed more drugs and PGx drugs than those who did not undergo PGx testing. The drugs used before and after PGx testing differed, and fewer drugs with reimbursement for pre-emptive PGx testing were included before PGx testing.

Conclusion: In Switzerland, personalized pharmacotherapy has the potential to be improved, as only 0.09% of the studied population underwent PGx testing, despite 77.4% claiming PGx drugs.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Safety 医学-毒理学

CiteScore

7.60

自引率

7.10%

发文量

112

审稿时长

6-12 weeks

期刊介绍： Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes: Overviews of contentious or emerging issues. Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics. Editorials and commentaries on topical issues. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.